Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Sudden-Onset Clear all
Completed Not applicable Interventional Results available

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

NCT06728059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 2 Interventional

A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

NCT01686620
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BIOD-123, Lispro (Humalog)
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Anaheim, California • Chula Vista, California • Concord, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

NCT01580813
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

NCT01836523
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

Stem Cell Therapy for Chronic Kidney Disease

NCT04869761
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D

NCT02746627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Positive Affect, Education
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 7, 2026, 3:32 PM EDT
Terminated Not applicable Interventional Results available

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

NCT03626623
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

NCT00417989
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 70 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 7, 2026, 3:32 PM EDT
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus

NCT06627517
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Sleep Quality
Interventions
Episodic overnight patch pump
Device
Lead sponsor
Luna Diabetes
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Walnut Creek, California • Aurora, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 7, 2026, 3:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 3:32 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

NCT06046833
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Gastroparesis With Diabetes Mellitus
Interventions
FreeStyle Libre 3 continuous glucose monitoring sensor, Nutritional drink
Device · Other
Lead sponsor
Samita Garg
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Evaluation of an Ascensia Blood Glucose Meter and App System

NCT02568384
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Onyx BG Meter / App System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 7, 2026, 3:32 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

NCT01919385
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Low Glucose Minimizer
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 1 Interventional

A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1

NCT00239148
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
E1 and G1
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation

NCT04510506
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas (AP)
Device
Lead sponsor
University of Virginia
Other
Eligibility
11 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 1Phase 2 Interventional

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

NCT04545411
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Dapagliflozin 10 MG [Farxiga], REMD-477, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 7, 2026, 3:32 PM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 7, 2026, 3:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes Mellitus Effect on Bone Mineral Density

NCT01633684
View directory record Official record
Conditions
Diabetes Mellitus, Osteoporosis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 7, 2026, 3:32 PM EDT
Not listed Not applicable Interventional

Exploratory Study of the Efficacy of Standard of Care Revascularization of the Lower Extremity

NCT04720170
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Revascularization
Procedure
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 7, 2026, 3:32 PM EDT
Completed No phase listed Observational

Clinical Startup of the 670G Closed Loop Insulin Delivery System

NCT03017482
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medtronic 670G
Device
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 7, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes

NCT03165786
View directory record Official record
Conditions
Type1diabetes
Interventions
FREE
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 3:32 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

NCT00700622
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Technosphere Insulin, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
20
States / cities
Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 7, 2026, 3:32 PM EDT